Anti-CD19 CAR-T for certain relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to sign informed consent
- Have relapsed or refractory lymphoma in one of these groups: Burkitt lymphoma or Marginal Zone Lymphoma / Lymphoplasmacytic Lymphoma (including Waldenström)
- Have a tumor marker test showing CD19 is present on your lymphoma cells (or it must be shown again on a recent biopsy if you had anti-CD19 treatment before)
- Have “measurable” active disease (for example PET-positive disease or, for some types, an IgM blood level above 0.5 g/dL)
- Have enough body strength and organ health (including good blood counts and heart function) for CAR-T cell collection and treatment
- Have no major recent exclusions (for example, no CAR-T against CD19 before, no recent transplant right before treatment, no HIV, and no active hepatitis infection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
Hear when a new Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.